Ayala Pharmaceuticals Inc

+0.03 (+0.30%)
Earnings Announcements

Ayala Pharmaceuticals Says Existing Cash Balance To Fund Operating Expenses And Capital Expenditure Requirements Into 2023

Published: 03/25/2021 12:34 GMT
Ayala Pharmaceuticals Inc (AYLA) - Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update.
Ayala Pharmaceuticals Inc - Existing Cash Balance to Fund Operating Expenses and Capital Expenditure Requirements Into 2023.
Revenue is expected to be $0.84 Million
Adjusted EPS is expected to be -$0.80

Next Quarter Revenue Guidance is expected to be $0.97 Million
Next Quarter EPS Guidance is expected to be -$0.74

More details on our Analysts Page.